Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...

Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago. These figures are ...

Stock futures are slightly higher Thursday morning after two straight days of gains have taken major indexes back near all-time highs.

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly & Co. said it expects to generate adjusted 2025 profit of $22.50 a share to $24 a share in 2025. That compares to the FactSet consensus estimate of $22.76 a share for 2025.

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...